Literature DB >> 4765719

Lymphocyte transformation and leucocyte migration-inhibition by Australia antigen.

A A Laiwah, A K Chaudhuri, J R Anderson.   

Abstract

Mesh：

Substances：

Year:  1973        PMID： 4765719      PMCID： PMC1553856     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  19 in total

1.  Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum.

Authors:  S Sherlock; R A Fox; S P Niazi; P J Scheuer
Journal:  Lancet       Date:  1970-06-13       Impact factor: 79.321

2.  Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma.

Authors:  C L Vogel; P P Anthony; N Mody; L F Barker
Journal:  Lancet       Date:  1970-09-26       Impact factor: 79.321

3.  Immune complexes in hepatitis.

Authors:  J D Almeida; A P Waterson
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

4.  Australia antigen in acute and chronic liver disease.

Authors:  R Wright; R W McCollum; G Klatskin
Journal:  Lancet       Date:  1969-07-19       Impact factor: 79.321

5.  An epidemic of hepatitis in a chronic-hemodialysis unit. Australia antigen and differences in host response.

Authors:  W T London; M Di Figlia; A Sutnick; B S Blumberg
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

6.  An antigen detected in the blood during the incubation period of serum hepatitis.

Authors:  A M Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1968-07       Impact factor: 11.205

7.  Cell migration inhibition factor released by antigen from human peripheral lymphocytes.

Authors:  D E Thor; R E Jureziz; S R Veach; E Miller; S Dray
Journal:  Nature       Date:  1968-08-17       Impact factor: 49.962

8.  An in vitro assay for cellular hypersensitivity in man.

Authors:  R E Rocklin; O L Meyers; J R David
Journal:  J Immunol       Date:  1970-01       Impact factor: 5.422

9.  Human lymphocyte migration as a parameter of hypersensitivity.

Authors:  M Soborg; G Bendixen
Journal:  Acta Med Scand       Date:  1967-02

10.  Australia antigen and hepatitis. Studies in asymptomatic people and lepromatous leprosy patient.

Authors:  B S Blumberg; L Melartin
Journal:  Arch Intern Med       Date:  1970-02
View more
  16 in total

1.  ad and ay subtypes of hepatitis B antigen in a case of hypogammaglobulinaemia.

Authors:  J W Lawton; R Hopkins; I C Paterson; P C Das
Journal:  J Clin Pathol       Date:  1975-11       Impact factor: 3.411

2.  Cell-mediated immunity to hepatitis B virus antigens in mice: correlation of in vivo and in vitro assays.

Authors:  P A De Moerloose; I H Frazer; W A Sewell; E J Collins; I R Mackay
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

3.  Acute hepatitis: significance of changes in complement components.

Authors:  J A Charlesworth; S Lawrence; P A Worsdall; L P Roy; C R Boughton
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

4.  Detection of cellular and humoral immunity to hepatitis B surface antigen (HBsAg) in asymptomatic HBsAg carriers.

Authors:  S P Sylvan; U B Hellström; P R Lundbergh
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

Review 5.  Immunological aspects of chronic active hepatitis.

Authors:  S Vento; A L Eddleston
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

6.  T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis b virus infection.

Authors:  A Alberti; G Realdi; F Bortolotti; A M Rigoli
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

7.  Organ-specificity and diagnostic value of cell-mediated immunity against a liver-specific membrane protein: studies in hepatic and non-hepatic diseases.

Authors:  K H Meyer zum Büschenfelde; A Alberti; W Arnold; J Freudenberg
Journal:  Klin Wochenschr       Date:  1975-11-15

8.  Immune response to hepatitis B surface antigen.

Authors:  A B Ibrahim; G N Vyas; H A Perkins
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

9.  Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen.

Authors:  J J Vallotton; P C Frei
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

10.  Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.

Authors:  F M Audibert; G Przewlocki; C D Leclerc; M E Jolivet; H S Gras-Masse; A L Tartar; L A Chedid
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.